Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof

• US 10,060,934 B2
• Filed: 11/18/2014
• Issued: 08/28/2018
• Est. Priority Date: 11/18/2013
• Status: Active Grant

• Current Assignee: NanoPharmaceuticals LLC
• Original Assignee: NanoPharmaceuticals LLC
• Inventors: Mousa, Shaker A., Davis, Paul J.
• Primary Examiner(s): Haghighatian, Mina
• Assistant Examiner(s): Hirt, Erin E
• Application Number:
  US14/546,440
• Publication Number:
  US 20150139934A1
• Time in Patent Office: 1,379 Days
• Field of Search: None
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/7014 (Neo)vascularisation - Angiogenesis
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/743 Steroid hormones
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors

Abstract

A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.

Claims

1. A method for screening a patient'"'"'s body fluid for a presence of angioinhibition resistance and treating the patient when angioinhibition resistance is identified, comprising the steps of:

collecting a first blood or serum sample from the patient before administering an anti-antiogenic agent;

administering to the patient the anti-angiogenic agent;

collecting a second blood or serum sample from the patient after administration of the anti-angiogenic agent to the patient;

performing, on the first blood or serum sample and the second blood or serum sample, a chich chorioallantoic membrane (CAM) model estimate of angiogenesis stimulation, with the CAM configured for using the first collected blood or serum sample and the second blood or serum sample from the patient to quantify a generation of new blood vessels from existing blood vessels and new blood vessel branches;

determining from the CAM using the patient'"'"'s second blood or serum sample as a function of comparing the generation of new blood vessels and branches before and after administering the anti-angiogenic agent an estimate of the patient'"'"'s angioinhibition resistance;

and treating the patient when the estimate of the patient'"'"'s angioinhibition resistance shows that the patient has angioinhibition resistance, wherein the step of treating the patient comprises inducing a state of subclinical hypothyroidism in the patient.

2. The method of claim 1 further comprising the step of identifying vascular branch points in the CAM angiogenesis assay, statistically comparing the CAM angiogenesis vascular branch points with blood or serum from a healthy patient and the second blood or serum sample collected after treatment with the anti-angiogenic agent.

3. The method of claim 1, wherein the anti-angiogenic agent is an anti-angiogenic thyroid hormone analog.

4. The method of claim 3, wherein the anti-angiogenic thyroid hormone analog is tetraiodothyroacetic acid (tetrac), triiodothyroacetic acid (triac), or a combination thereof.

5. The method of claim 4, wherein the anti-angiogenic thyroid hormone analog is further conjugated to a polymer, wherein the polymer is a nanoparticle.

6. The method of claim 5, wherein the polymer is selected from the group consisting of polyvinyl alcohol, acrylic acid ethylene co-polymer, polyethylene glycol (PEG), methoxypolyethylene glycol-poly(lactide-co-glycolide), polyacrylic acid, polylactic acid, agarose, polyglycolide, polyethylene oxide, m-PEG, polyvinyl alcohol, polyglycolic acid, poly-L-lysine, Human Serum Albumin, carboxymethylcellulose derivatives, carboethylcellulose derivatives, carboxyhydroxypropylcellulose derivatives, hyaluronic acid, folate linked cyclodextrin, folate linked dextran, alginate, carrageenan, chitosan, dextran, collagen, polyamine, poly aniline, poly alanine, polytrytophan, poly tyrosine, polylactide-co-glycolide, poly(lactic-co-glycolic) acid (PLGA), polylysyl glycolide, polyglycolide, polylactide, or co-polymers thereof.

7. The method of claim 1, wherein the step of treating the patient further comprises administering a compound to the patient after inducing the state of subclinical hypothyroidism, wherein the compound is an anti-angiogenic agent, and anti-angiogenic agent encapsulating a chemotherapeutic agent, an anti-angiogenic agent encapsulating an anti-inflammatory agent, or a combination of compounds thereof.

8. The method of claim 1, wherein the step of inducing the state of subclinical hypothyroidism, includes the step of raising thyroid stimulating hormone (TSH) to approximately greater than 3.04 μ

IU/mL, by administering to the patient an anti-thyroid agent, decreasing the patient'"'"'s production of the pro-angiogenic non-peptide hormone.

9. The method of claim 8, wherein the pro-angiogenic non-peptide hormone is a concentration of free T₄ or T₃.